Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1

Interventions

Specimen Handling 322Magnetic Resonance Spectroscopy 219Biopsy 186Nivolumab 50X-Rays 45Radiation 42Immunoglobulin G 42Disulfides 42Paclitaxel 40Cyclophosphamide 40pembrolizumab 39Taxes 39Cisplatin 39Platinum 371,2-diaminocyclohexaneplatinum II citrate 37Carboplatin 36Radiotherapy 33atezolizumab 30Doxorubicin 30olaparib 25Gemcitabine 25venetoclax 24Ipilimumab 24CTLA-4 Antigen 24Bevacizumab 24Prednisone 22Vincristine 21Phantoms, Imaging 21cabozantinib 20durvalumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Iodine-124 × 30 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡